[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.66.254. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Brief Report
Resident's Forum
November 2013

Multidisciplinary Management of Focal Nodular Hyperplasia in ChildrenExperience With 10 Cases

Author Affiliations
  • 1Department of Surgery, Howard University Hospital, Washington, DC
  • 2Division of Pediatric Surgery, University of Illinois Medical Center, Chicago
  • 3Department of General Surgery, Brigham and Women’s Hospital, Boston, Massachusetts
  • 4Division of Pediatric Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland
JAMA Surg. 2013;148(11):1068-1070. doi:10.1001/jamasurg.2013.351
Abstract

Nonoperative management of focal nodular hyperplasia (FNH) is an accepted paradigm in adults, but current management strategies for children vary substantially between institutions. We reviewed medical records at Johns Hopkins Hospital between January 1, 1998, and December 31, 2008, to investigate the diagnosis, treatment, and outcome of pediatric patients with a pathologic diagnosis of FNH to provide additional data to help formulate management guidelines for this disease. Ten pediatric patients were identified as having a pathologic diagnosis of FNH, either by biopsy sample (n = 5) or hepatic resection (n = 5). The mean age of the patients was 12.1 years, and most were female (n = 7). Mean tumor size was 5.7 cm (range, 0.8-13 cm). Four of 5 patients whose FNH was diagnosed by biopsy alone developed no sequelae, and 1 patient eventually required surgery for mass effect. Patients with either large lesions (≥5 cm) or symptoms were referred for resection. Observational management of small lesions that can be confidently diagnosed as FNH appears to be safe and appropriate. Surgical resection should be reserved for large or symptomatic lesions amenable to resection.

Focal nodular hyperplasia (FNH) represents a benign lesion that accounts for 2% of all pediatric hepatic tumors, which are themselves rare.1,2 The pathogenesis of the lesion is presumed to involve hyperplasia rather than a primary neoplastic process, with hepatocytes responding to a congenital vascular anomaly. Focal nodular hyperplasia appears radiographically as a lobulated mass with a central stellate scar. Histologically, a well-circumscribed lesion is seen, surrounded by a thin fibrous layer with a central scar and radiating septa containing bile ducts, blood vessels, and lymphocytes.3 Most lesions are noted as a painless mass or are found incidentally.4,5

Although nonoperative management with observation has been deemed appropriate in adults, a higher percentage of pediatric liver tumors are malignant, requiring diagnostic certainty to be of even higher importance.6 As a result, and because of symptoms from relatively smaller lesions than in adults, surgical resection of FNH is more common in children. In the present report, we review the diagnosis, management, and outcome for children at our institution with a pathologic diagnosis of FNH to provide additional data toward development of a coherent management strategy for this disease.

Methods

Following approval by the institutional review board of the Johns Hopkins Hospital, a review of the medical records of all patients with a pathologic diagnosis of FNH between 1984 and 2008 at Johns Hopkins Hospital was undertaken. Data were collected on age at diagnosis, sex, location and size of lesion, symptoms, associated diagnoses, radiographic findings, treatment options, and clinical outcomes.

Results

A total of 10 pediatric patients were identified between 1984 and 2008 as having a pathologic diagnosis of FNH by either biopsy sample (n = 5) or hepatic resection specimen (n = 5). Seven patients were female, and the mean age was 12.1 years (range, 23 months-19 years) (Table) at the time of diagnosis. Patient 7 presented with nonspecific abdominal or epigastric pain, 4 (patients 2, 3, 5, and 9) presented with painless right upper quadrant masses, 2 masses (patients 8 and 10) were detected incidentally during workup of abdominal or pelvic pain with a nonhepatic source, and 3 masses (patients 1, 4, and 6) were identified in screening for unrelated genetic or oncologic conditions. All 10 patients had aspartate aminotransferase, alanine aminotransferase, and α-fetoprotein levels within normal limits at presentation. Three patients had prior exogenous estrogen exposure.

Table.  
Clinical Characteristics, Treatment, and Outcomes of 10 Pediatric Patients With Focal Nodular Hyperplasia
Clinical Characteristics, Treatment, and Outcomes of 10 Pediatric Patients With Focal Nodular Hyperplasia

Four of the 5 patients who underwent biopsy were monitored conservatively without sequelae after a mean follow-up time of 20 months (range, 3-53 months). One patient who received an initial recommendation for observation developed a symptomatic decrease in liver function, causing ascites (Table, patient 5). Generally, patients with lesions 5 cm or larger, without histologic diagnostic certainty, or with symptoms received a recommendation to undergo resection. Surgery ranged from wedge resection to trisegmentectomy. There were no surgical complications. Mean tumor size overall was 5.7 cm (range, 0.8-13 cm) (Table). The mean size of resected lesions was 7.0 cm, and the mean lesion size from patients whose treatment was managed nonoperatively was 1.9 cm.

Discussion

There are no standardized treatment guidelines for the treatment of FNH in children. Thus, we undertook a retrospective study of children with FNH at our institution to gather further evidence to support development of a cohesive management strategy. Our review supports observational management of small asymptomatic FNH lesions, with surgical resection reserved for both symptomatic and large asymptomatic lesions amenable to resection.

The demographics of our cohort and the manners of presentation are similar to those of previous work by Reymond et al4 and Yang et al,7 although our patients less frequently experienced right upper quadrant pain (20% vs 55% and 61.5%). Selection of our observational group was based on size of the lesion (mean 1.9 cm) and symptoms. None of these patients experienced growth, rupture, bleeding, or malignant degeneration of their observed lesions. We strongly suspect a natural history of negligible tumor growth and possibly regression of FNH lesions of the liver, which suggest the beneficial nature of conservative management. Diagnosis of FNH mainly relies on imaging examinations: ultrasonography, computed tomography, and/or magnetic resonance imaging. Magnetic resonance imaging is probably the best noninvasive imaging modality for FNH, with a specificity of 98% and a sensitivity of 70%.8 Specific characteristics include uniform isointesity or hypointensity on T1-weighted images, mild hyperintensity with a central scar on T2-weighted imaging, and delayed arterial enhancement. Differentiation of FNH from fibrolamellar hepatocellular carcinoma (hypointense central scar on T2-weighted images) can be based on radiographic characteristics with high accuracy.9 Kamel et al,10 using 16–multi-detector computed tomography and 3-dimensional computed tomographic angiography, reported that imaging alone can be used to accurately diagnose FNH, saving the patient potential risks of biopsy and surgery. Yang et al,7 however, found only 6 cases (46.2%) that were correctly diagnosed as FNH preoperatively on the basis of imaging and fine-needle aspiration biopsy. In their review, Nguyen et al3 reported a series of 51 women with preoperative assessment of benign liver disease; of those patients, 18 had a diagnosis of FNH. Of patients in the series, 36 received diagnoses postoperatively of FNH; 12 patients, of hepatic adenoma; and 3, of hepatocellular carcinoma. In our series, 3 of the 10 patients had an unclear image-only assessment. Of the remaining 7, only 2 received correct preoperative diagnoses based on imaging and fine-needle aspiration biopsy. The other lesions preoperatively identified were hepatoblastoma (1 lesion), metastatic Langerhans sarcoma (1), hepatic adenoma (2), and hepatic mass (1). This underscores the necessity of open biopsy to confirm a diagnosis when ambiguity exists in the imaging of fine-needle pathologic data surrounding hepatic lesions. Furthermore, although prior chemotherapy may increase risk for developing FNH,1115 we are always careful to exclude metastatic or recurrent disease before recommending surveillance alone.

Patients with symptomatic large, unresectable FNH lesions pose a unique problem. Embolization and vascular occlusion studies1618 have shown promise in the treatment of difficult lesions. These approaches may shrink lesions to a size more amenable to resection or ablate them such that no further therapy is needed. These therapies also could be used for small lesions that are difficult to resect because of their central location. There is efficacy of embolization with diminution in the size of the lesion, and in some cases total ablation is possible. Radiofrequency ablation may be another modality to use in patients with small yet anatomically difficult lesions, as was demonstrated in one of our patients who underwent resection combined with radiofrequency ablation for a satellite lesion (patient 10). The efficacy of radiofrequency ablation alone for small asymptomatic lesions has not been studied.

In summary, the present study supports a management paradigm of conservative observational management of small asymptomatic FNH lesions, with surgical extirpation reserved for symptomatic and possibly large asymptomatic lesions amenable to resection. Embolization and vascular occlusion are modalities new to the field but offer a less morbid outcome and possible advantage in dealing with unresectable or large (symptomatic and asymptomatic) lesions. It is unclear at this time whether embolization confers any additional benefit to surgical ablation or even to observational management of small asymptomatic lesions; this approach requires additional study.

Back to top
Article Information
Section Editor: Richard D. Schulick, MD, MBA; Pamela A. Lipsett, MD, MPHE.

Accepted for Publication: February 14, 2013.

Correspondence: Fizan Abdullah, MD, PhD, Division of Pediatric Surgery, The Johns Hopkins University School of Medicine, 600 N Wolfe St, Harvey 319, Baltimore, MD 21287 (fa@jhmi.edu).

Published Online: September 18, 2013. doi:10.1001/jamasurg.2013.351.

Author Contributions:Study concept and design: Price, Abdullah.

Acquisition of data: Price, Choo, Abdullah.

Analysis and interpretation of data: All authors.

Drafting of the manuscript: Ortega Price, Choo, Abdullah.

Critical revision of the manuscript for important intellectual content: Ortega, Price, Goldstein, Stewart, Abdullah.

Statistical analysis: Ortega, Price, Choo, Abdullah.

Administrative, technical, or material support: Ortega, Price, Choo, Goldstein, Abdullah.

Study supervision: Price, Stewart, Abdullah.

Conflict of Interest Disclosures: None reported.

References
1.
Mowat AP. Liver Disorders in Childhood. 2nd ed. London, England: Butterworth; 1987:324-336.
2.
Greenberg M, Filler RM. Hepatic tumors. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. Philadelphia, PA: Lippincott; 1989:569-582.
3.
Nguyen  BN, Fléjou  J-F, Terris  B, Belghiti  J, Degott  C.  Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol. 1999;23(12):1441-1454.
PubMedArticle
4.
Reymond  D, Plaschkes  J, Lüthy  AR, Leibundgut  K, Hirt  A, Wagner  HP.  Focal nodular hyperplasia of the liver in children: review of follow-up and outcome. J Pediatr Surg. 1995;30(11):1590-1593.
PubMedArticle
5.
Stocker  JT, Ishak  KG.  Focal nodular hyperplasia of the liver: a study of 21 pediatric cases. Cancer. 1981;48(2):336-345.
PubMedArticle
6.
Di Stasi  M, Caturelli  E, De Sio  I, Salmi  A, Buscarini  E, Buscarini  L.  Natural history of focal nodular hyperplasia of the liver: an ultrasound study. J Clin Ultrasound. 1996;24(7):345-350.
PubMedArticle
7.
Yang  Y, Fu  S, Li  A,  et al.  Management and surgical treatment for focal nodular hyperplasia in children. Pediatr Surg Int. 2008;24(6):699-703.
PubMedArticle
8.
Vogl  TJ, Own  A, Hammerstingl  R, Reichel  P, Balzer  JO.  Transarterial embolization as a therapeutic option for focal nodular hyperplasia in four patients. Eur Radiol. 2006;16(3):670-675.
PubMedArticle
9.
Kuo  P-H, Lai  HS, Huang  SY, Liu  KL.  Focal nodular hyperplasia of the liver in an 8-year-old boy. Surgery. 2007;142(3):422-423.
PubMedArticle
10.
Kamel  IR, Liapi  E, Fishman  EK.  Focal nodular hyperplasia: lesion evaluation using 16-MDCT and 3D CT angiography. AJR Am J Roentgenol. 2006;186(6):1587-1596.
PubMedArticle
11.
Zhang  SH, Cong  WM, Wu  MC.  Focal nodular hyperplasia with concomitant hepatocellular carcinoma: a case report and clonal analysis. J Clin Pathol. 2004;57(5):556-559.
PubMedArticle
12.
Langrehr  JM, Pfitzmann  R, Hermann  M,  et al.  Hepatocellular carcinoma in association with hepatic focal nodular hyperplasia. Acta Radiol. 2006;47(4):340-344.
PubMedArticle
13.
Gutweiler  JR, Yu  DC, Kim  HB,  et al.  Hepatoblastoma presenting with focal nodular hyperplasia after treatment of neuroblastoma. J Pediatr Surg. 2008;43(12):2297-2300.
PubMedArticle
14.
Joyner  BL  Jr, Levin  TL, Goyal  RK, Newman  B.  Focal nodular hyperplasia of the liver: a sequela of tumor therapy. Pediatr Radiol. 2005;35(12):1234-1239.
PubMedArticle
15.
Bouyn  CI, Leclere  J, Raimondo  G,  et al.  Hepatic focal nodular hyperplasia in children previously treated for a solid tumor: incidence, risk factors, and outcome. Cancer. 2003;97(12):3107-3113.
PubMedArticle
16.
Soucy  P, Rasuli  P, Chou  S, Carpenter  B.  Definitive treatment of focal nodular hyperplasia of the liver by ethanol embolization. J Pediatr Surg. 1989;24(10):1095-1097.
PubMedArticle
17.
Shuda  K, Tokunaga  A, Sohda  T,  et al.  Focal nodular hyperplasia treated by transcatheter arterial embolization using Lipiodol mixed with Gelfoam particles. J Gastroenterol Hepatol. 2001;16(7):840-841.
PubMedArticle
18.
Geschwind  JF, Degli  MS, Morris  JM, Choti  MA.  Treatment of focal nodular hyperplasia with selective transcatheter arterial embolization using iodized oil and polyvinyl alcohol. Cardiovasc Intervent Radiol. 2002;25(4):340-341.
PubMedArticle
×